Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Chubb
Chinese Patent Office
Colorcon
QuintilesIMS
Daiichi Sankyo
Novartis
McKesson
Moodys
Deloitte

Generated: February 21, 2018

DrugPatentWatch Database Preview

Osmotica Pharm Company Profile

« Back to Dashboard

What is the competitive landscape for OSMOTICA PHARM, and what generic and branded alternatives to OSMOTICA PHARM drugs are available?

OSMOTICA PHARM has six approved drugs.



Summary for Osmotica Pharm
US Patents:0
Tradenames:5
Ingredients:5
NDAs:6

Drugs and US Patents for Osmotica Pharm

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Osmotica Pharm VENLAFAXINE HYDROCHLORIDE venlafaxine hydrochloride TABLET, EXTENDED RELEASE;ORAL 022104-004 May 20, 2008 AB RX Yes No ➤ Sign Up ➤ Sign Up
Osmotica Pharm VENLAFAXINE HYDROCHLORIDE venlafaxine hydrochloride TABLET, EXTENDED RELEASE;ORAL 022104-003 May 20, 2008 AB RX Yes Yes ➤ Sign Up ➤ Sign Up
Osmotica Pharm Corp KHEDEZLA desvenlafaxine TABLET, EXTENDED RELEASE;ORAL 204683-002 Jul 10, 2013 BC RX No No ➤ Sign Up ➤ Sign Up
Osmotica Pharm Us NIFEDIPINE nifedipine TABLET, EXTENDED RELEASE;ORAL 077127-001 Nov 21, 2005 AB2 RX No No ➤ Sign Up ➤ Sign Up
Osmotica Pharm VENLAFAXINE HYDROCHLORIDE venlafaxine hydrochloride TABLET, EXTENDED RELEASE;ORAL 022104-002 May 20, 2008 AB RX Yes No ➤ Sign Up ➤ Sign Up
Osmotica Pharm Corp KHEDEZLA desvenlafaxine TABLET, EXTENDED RELEASE;ORAL 204683-001 Jul 10, 2013 BC RX No No ➤ Sign Up ➤ Sign Up
Osmotica Pharm Us OXYBUTYNIN CHLORIDE oxybutynin chloride TABLET, EXTENDED RELEASE;ORAL 078503-001 Feb 4, 2009 AB RX No No ➤ Sign Up ➤ Sign Up
Osmotica Pharm Us NIFEDIPINE nifedipine TABLET, EXTENDED RELEASE;ORAL 077410-001 Oct 3, 2007 AB2 RX No No ➤ Sign Up ➤ Sign Up
Osmotica Pharm Us OXYBUTYNIN CHLORIDE oxybutynin chloride TABLET, EXTENDED RELEASE;ORAL 078503-002 Feb 4, 2009 AB RX No No ➤ Sign Up ➤ Sign Up
Osmotica Pharm Us DONEPEZIL HYDROCHLORIDE donepezil hydrochloride TABLET;ORAL 203114-001 Jan 26, 2016 AB RX No No ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Osmotica Pharm

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Osmotica Pharm VENLAFAXINE HYDROCHLORIDE venlafaxine hydrochloride TABLET, EXTENDED RELEASE;ORAL 022104-001 May 20, 2008 6,403,120 ➤ Sign Up
Osmotica Pharm VENLAFAXINE HYDROCHLORIDE venlafaxine hydrochloride TABLET, EXTENDED RELEASE;ORAL 022104-002 May 20, 2008 6,419,958 ➤ Sign Up
Osmotica Pharm VENLAFAXINE HYDROCHLORIDE venlafaxine hydrochloride TABLET, EXTENDED RELEASE;ORAL 022104-003 May 20, 2008 6,403,120 ➤ Sign Up
Osmotica Pharm VENLAFAXINE HYDROCHLORIDE venlafaxine hydrochloride TABLET, EXTENDED RELEASE;ORAL 022104-004 May 20, 2008 6,403,120 ➤ Sign Up
Osmotica Pharm VENLAFAXINE HYDROCHLORIDE venlafaxine hydrochloride TABLET, EXTENDED RELEASE;ORAL 022104-004 May 20, 2008 6,419,958 ➤ Sign Up
Osmotica Pharm VENLAFAXINE HYDROCHLORIDE venlafaxine hydrochloride TABLET, EXTENDED RELEASE;ORAL 022104-003 May 20, 2008 6,419,958 ➤ Sign Up
Osmotica Pharm VENLAFAXINE HYDROCHLORIDE venlafaxine hydrochloride TABLET, EXTENDED RELEASE;ORAL 022104-001 May 20, 2008 6,419,958 ➤ Sign Up
Osmotica Pharm VENLAFAXINE HYDROCHLORIDE venlafaxine hydrochloride TABLET, EXTENDED RELEASE;ORAL 022104-002 May 20, 2008 6,403,120 ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Colorcon
Harvard Business School
Fuji
Daiichi Sankyo
Dow
Moodys
Federal Trade Commission
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot